Cartwheel Signs Letter of Intent to License Clearsight Therapeutics' Novel Pink Eye Treatment for 2027 Portfolio Expansion
illi News/10318607

DALLAS - illiNews -- Cartwheel, a mission-driven company providing innovative first aid solutions for families, has signed a letter of intent (LOI) to license Clearsight Therapeutics' over-the-counter pink eye treatment beginning in 2027. The agreement marks a strategic addition to Cartwheel's expanding portfolio of accessible, family-friendly health products.

"Cartwheel is committed to bringing first aid into the 21st century by offering modern, effective solutions for everyday health challenges," said Joanna Shu, CEO of Cartwheel. "This new addition fits squarely within our mission to support families with products they can trust, and we're thrilled to work with Clearsight Therapeutics to help bring their innovative eye drop to market."

Clearsight Therapeutics was founded by eye care industry veterans to develop better solutions for common eye conditions that impact millions of people each year. Their novel pink eye treatment is designed to be safe, effective, and accessible - aligning closely with Cartwheel's vision for consumer-first care.

More on illi News

• Record Revenues, Debt-Free Momentum & Shareholder Dividend Ignite Investor Attention Ahead of 2026–2027 Growth Targets: IQSTEL (N A S D A Q: IQST)
• New YouTube Channel Pair Launches to Bring Entertainment Nostalgia Back to Life
• BRAG Hosts Holiday Benefit — Awards 10 Student Scholarships & Honors Timberland with the Corporate Impact Award
• FittingPros Launches Industry's First Data-Driven Golf Club Fitting Directory
• Englewood Shines Bright as GECC Announces 2025 Window Wonderland Participants

"We built Clearsight to reimagine what patient-centric treatment can look like," said Patrick Smale, CEO of Clearsight Therapeutics. "Partnering with Cartwheel ensures this product gets into the hands of the families who need it most. Their team understands the value of innovation, and we're proud to align our mission with theirs."

"The need for accessible, over-the-counter ophthalmic solutions continues to grow," said Jai G. Parekh, MD, MBA, Co-Founder and CEO of EyeCare Consultants of New Jersey and Chief of Cornea at St. Joseph's HealthCare System, NJ. "This partnership between Clearsight and Cartwheel represents a thoughtful, science-backed step toward meeting that demand. It's exciting to see mission-driven companies collaborating to make a real difference in patient care."

The companies will collaborate over the next 12 months to finalize the licensing terms and prepare for regulatory and go-to-market planning, with a commercial launch anticipated in 2027.

More on illi News

• Take Control of Your Color Matching with Boston Industrial Solutions' Newly Expanded Natron® UVPX Series Ink Colors
• "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
• Kaufman Development Breaks Ground on Detroit Micro Data Center, Expanding Its National AI Platform
• Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
• $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU

About Cartwheel

Cartwheel is an innovative healthcare company transforming the future of first aid with safe, effective, and science-backed solutions. By combining cutting-edge technology with natural alternatives, Cartwheel is reimagining the household medicine cabinet - offering modern treatments for common concerns like lice and pink eye. Learn more at www.gocartwheel.com.

About Clearsight Therapeutics

Clearsight Therapeutics was founded by a team of eye care industry veterans and partners to develop better solutions to common eye conditions such as dry eye and pink eye, which continue to disrupt the lives of millions of patients. Clearsight is committed to ethical and responsible biotech research and development. Learn more at www.clearsighttx.com.